Bionexus Gene Lab Corp. — Form 10-Q Summary
Business context and reporting period
The filing covers the quarter and nine months ended September 30, 2019. Bionexus Gene Lab Corp. is a Wyoming holding company operating primarily through its Malaysian subsidiary. The company develops molecular diagnostic and blood-based genomic screening technology intended to support early disease detection and personalized health management. Its laboratory and blood collection operations are located in Malaysia.
Key financial metrics
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $24,173 | $91,625 | $73,906 | $202,921 |
| Gross profit | $7,674 | $22,370 | $21,565 | $35,490 |
| Gross margin | 31.8% | 24.4% | 29.2% | 17.5% |
| Operating income (loss) | $(50,138) | $(55,142) | $(179,560) | $123,247 |
| Net income (loss) | $(22,028) | $(88,962) | $(153,892) | $89,427 |
| Comprehensive income (loss) | $(32,830) | $(82,529) | $(165,148) | $83,180 |
- Cash and bank balances were $370,516 at September 30, 2019. Fixed deposits were $606,633, producing reported cash and cash equivalents of $977,149.
- Working capital was $989,182, compared with $1,235,461 at December 31, 2018.
- Total assets were $1.34 million and total liabilities were $80,626. The principal debt-like obligation was a finance lease with a net present value of $68,611, including $19,517 current and $49,094 non-current.
- Operating cash flow was $(158,911), investing cash flow was $(5,672), and financing cash flow was $(107,333) for the first nine months. Cash and cash equivalents declined by $283,090.
- Weighted-average basic and diluted shares were 73,697,558; reported basic and diluted loss per share rounded to zero.
Material changes versus prior comparable periods
- Third-quarter revenue declined by approximately 74%, primarily because of fewer patient referrals from local hospitals. Nine-month revenue declined by approximately 64%.
- Gross margins improved to approximately 32% in the quarter and 29% year to date, attributed to lower laboratory consumable prices and complimentary reagent kits related to the NHI project.
- Third-quarter operating loss narrowed modestly because of lower general and administrative expenses. Nine-month operations shifted from a $123,247 profit to a $179,560 loss, reflecting lower revenue, the absence of a prior-year $263,001 debt waiver recorded in other income, and higher professional fees, depreciation, renovations, and furniture and fixture costs.
- Other income fell to $19,684 for the first nine months from $271,266 in the prior-year period. The prior-year amount included the debt waiver; current-period interest income benefited from placing excess funds in short-term fixed instruments.
- Stockholders’ equity declined to $1.26 million from $1.52 million at December 31, 2018, primarily due to the nine-month net loss, foreign-currency translation losses, and disposal of 930,000 shares.
Outlook, commentary, risks, contingencies, and unusual items
- On August 1, 2019, the Malaysian subsidiary entered into a research agreement with Malaysia’s National Heart Institute and a principal investigator to develop blood-based genomic signatures for acute myocardial infarction risk prediction. The project was expected to run through February 28, 2020, with fees of approximately $1,100 per month. Management expected to develop a gene panel within two to three months and hoped the Institute would later incorporate the screening into regular patient screening; these are aspirations, not firm guidance.
- Management stated that available cash flow and resources should sustain the current level of operations for at least the next 12 months, while identifying potential liquidity pressures from hiring, website development, increased marketing, and public-company costs.
- Key disclosed risks include limited operating history and growth, uncertainty regarding the efficacy of the blood-screening process, potential product-liability claims without insurance coverage, and risks of operating in Malaysia, including enforcement of judgments against the subsidiary and management.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective and identified material weaknesses related to insufficient segregation of duties, reliance on a single officer and director, and the lack of a functioning audit committee with sufficient independent members. Remediation may be delayed by limited financial resources.
- The company reported no material pending legal proceedings, no material off-balance-sheet arrangements, and no contractual obligations beyond those reflected in the financial statements.
- On September 1, 2019, the company entered into consulting agreements covering a total of 12 million common shares. One-third vested upon execution, with additional shares contingent on specified promotional events and qualifying transactions. The filing separately reports 109,376,225 shares outstanding as of November 8, 2019, versus 73,697,558 shares outstanding in the September 30 balance sheet.
Important facts for investors to verify
- Reconcile the reported November 8 share count of 109,376,225 with the 73,697,558 shares reported at September 30 and the 12 million shares subject to consulting agreements.
- Assess whether patient referrals and revenue can recover, particularly after completion of the National Heart Institute research project.
- Verify the commercial validation, regulatory status, clinical efficacy, and adoption prospects of the company’s RNA and blood-screening technology.
- Monitor cash burn, fixed-deposit availability, finance-lease payments, and the company’s ability to fund operations without additional financing.
- Evaluate remediation of the disclosed material weaknesses, including segregation of duties, board independence, and audit committee oversight.
- Separate recurring operating performance from unusual items, especially the $263,001 prior-year debt waiver and current-period complimentary reagent kits.